Avenue Biosciences has built what it says is the first platform capable of measuring and modulating the cellular secretory pathway at scale, coupling massively parallel wet-lab screening of 5,000–6,000 signal peptide variants with machine-learning models. By identifying optimal peptide “addresses” in a single experiment, the technology can rescue stalled projects and shave years off traditional, sequential trial-and-error workflows. Originating from years of research at the University of Helsinki, the platform already serves contract development and manufacturing organizations (CDMOs) and pharmaceutical companies, and the firm generated revenue in its first year after emerging from stealth at the end of 2024. Investors see the approach as a route to lowering costs and unlocking complex biologics that have previously failed due to poor expression yields. The company combines experimental data with computational insights, continually refining prediction tools as scientific understanding deepens. With total capital raised now at $8.7 million, Avenue plans to channel fresh funds into expanding its team of wet-lab scientists and strengthening its scientific capabilities before broader commercial scale-up.

Total raised

$8M

Funding rounds

2

Latest round

Seed

Latest activity

Jan 2026